If you take NMN or NR to hold on to muscle as you age, you probably picture the NAD+ going straight into your muscle fibers. A new mouse study suggests the story may be stranger. Part of the benefit appeared to start in fat tissue, which responded to higher NAD+ by sending a protective signal through the blood to muscle.
This is animal research. It does not tell us what NMN or NR will do in people. It does offer an unusual look at how NAD+ biology might work across organs.
The surprise: a messenger from fat
The paper, published in Cell Metabolism by Liang, Li and colleagues at the Chinese Academy of Medical Sciences and Peking Union Medical College, starts with a familiar problem. Loss of skeletal muscle mass is a major driver of frailty and disability. Researchers still don't fully understand how whole-body metabolic cues protect muscle.
The team identified Serpina3n, an adipokine (a signaling protein released by fat tissue), as a key mediator of the muscle-protective effects of NAD+ supplementation in their models.
The proposed chain of events, as described in the abstract:
- NAD+ rises in adipose tissue.
- This activates STAT1-dependent transcription of the Serpina3n gene.
- Serpina3n is released into the bloodstream.
- Muscle is protected against atrophy.
This is a different picture from the usual one, in which NAD+ precursors act mainly inside the muscle cell. Here, fat functions as a sensing and signaling organ that converts a metabolic cue into a message for muscle.
Protection across three different kinds of muscle loss
The protective effect was reported across models of aging, disuse and cancer cachexia. These differ in important ways:
- Aging-related loss develops slowly and involves hormonal, inflammatory and metabolic changes.
- Disuse atrophy follows immobilization or inactivity, such as bed rest or a cast.
- Cancer cachexia is a severe wasting syndrome driven by tumor-related inflammation and metabolic disruption.
A mechanism that held up in all three suggests it touches something fairly basic about how muscle maintains itself. The abstract doesn't say how large the effects were in each model, so the strength of protection can't be judged from the summary alone. Models are also not the same as the human conditions they imitate.
What Serpina3n does inside muscle
Once Serpina3n reaches muscle, the authors report that it preserves pyruvate carboxylase protein levels. Pyruvate carboxylase is a mitochondrial enzyme that feeds the TCA cycle, the central energy-producing pathway of the cell. That process is called anaplerosis.
In simple terms, the TCA cycle needs a steady supply of intermediates, and anaplerosis keeps them topped up. According to the authors, keeping pyruvate carboxylase intact supports three things:
- anaplerosis,
- oxidative metabolism,
- protein synthesis.
This fits a broader view that muscle wasting is partly a metabolic problem. If the cell's energy and building-block supply falters, protein breakdown can outpace protein building. Serpina3n appears to help hold that machinery together.
The patent and what it signals
The conflict-of-interest statement notes that three authors (J.L., N.L. and J.H.) filed a provisional patent on using Serpina3n as a strategy to treat muscle atrophy. That is common in translational research and doesn't invalidate the findings, but it shows where the authors see the commercial potential: a targeted protein-based approach, not a supplement. Independent replication will matter.
What this means for NMN and NR users
The temptation is to read this as a reason to feel better about a supplement stack. Some caution is needed.
What it does suggest:
- NAD+ biology may work through inter-organ communication, not only direct effects in muscle.
- Fat tissue may be an important and overlooked part of how NAD+ boosting influences muscle.
What it does not show:
- It does not show that taking NMN or NR raises Serpina3n in people. The summary doesn't address specific precursors or human dosing, and none should be inferred.
- It does not show that any dose, form or schedule protects human muscle.
- It does not show that Serpina3n works the same way in humans, or that it is safe to raise.
The study is mouse work, and the abstract doesn't report human data. Many promising findings in rodents fail to translate, partly because mouse and human NAD+ metabolism and body composition differ.
Pairing with resistance training
Nothing in this paper tests exercise, so any link here is inference. Still, the practical hierarchy for muscle preservation is clear from other work: resistance training and adequate protein intake are the best-established tools for maintaining muscle with age. A supplement, if it helps at all, would be an add-on to those basics rather than a replacement.
It also fits that disuse was one of the models studied. Staying active is the most direct way to avoid disuse atrophy, whatever happens to NAD+ levels.
Open questions
- Do NAD+ precursors raise Serpina3n in human fat tissue? The abstract doesn't say, and this is the key translational question.
- Is there a human equivalent? Serpina3n is a mouse protein; the closest human relative is SERPINA3, and how well the findings carry over isn't established here.
- Is raising Serpina3n safe long term? Serpins regulate proteases and inflammation, so systemic elevation could have effects beyond muscle.
- How does body composition matter? If fat tissue is the source, people with very low or very high fat mass, or with dysfunctional adipose tissue, may respond differently.
- Does it add to exercise? Combination studies would be needed.
The bottom line
This study offers an intriguing new idea: NAD+ may protect muscle partly by prompting fat tissue to release Serpina3n, which helps muscle keep a key metabolic enzyme and sustain protein synthesis. It is a mechanistic mouse finding, not a supplementation guideline. For now, the sensible takeaway is curiosity rather than change: keep training, eat enough protein, and treat NMN and NR as unproven for muscle preservation in humans until clinical data arrive.